Analyst Coverage

MST ACCESS | CAR-iNKT, next gen cancer killer. Cutting-edge. Human trials start CY25. Undervalued.

A$0.34 valuation

SPARK PLUS | Describes Arovella’s current product pipeline and its ambitions to tackle a range of blood cancers and solid tumours.